Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Revenue projections:

Revenue projections for TMO
Revenue projections for TMO

TMO is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 1.890000
forwardPE 19.274206
debtToEquity 77.255000
earningsGrowth 0.093000
revenueGrowth 0.072000
grossMargins 0.410760
operatingMargins 0.211710
trailingEps 17.740000
forwardEps 26.918880

A current ratio of 1.89 for TMO implies that the company has ample liquidity to meet its short-term debts. TMO's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
TMO's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Positive gross and operating margins for TMO demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
Thermo Fisher Scientific Inc.'s forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting Thermo Fisher Scientific Inc. to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for TMO
Price projections for TMO

TMO's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about TMO's ability to generate strong results going forward.

Insider Transactions:

Insider Transactions for TMO
Insider Transactions for TMO


There were 25 Thermo Fisher Scientific Inc. stock sales, with market price at 532.900400390625.Throughout the period under consideration, there were no sell transactions.With more buys than sells around TMO's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for TMO
Recommendations trend for TMO


Thermo Fisher Scientific Inc. has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Thermo Fisher Scientific Inc. as a stable option to park their money and potentially benefit from the company's continued growth and profitability.